Evidence map›Paper›PMID 23450875›Full record

ArticlePublic health reports (Washington, D.C. : 1974)

Mortality rates and age at death from sickle cell disease: U.S., 1979-2005.

Sophie Lanzkron, C Patrick Carroll, Carlton Haywood

5 registry-linked trialsAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Public health reports (Washington, D.C. : 1974). The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 213 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
213citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03240731 phase2completednot on this map

Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell Disease

TypeinterventionalSponsorCentre Hospitalier Intercommunal CreteilRan2017 to 2024Enrolled25ConditionsSickle Cell DiseaseArmsbone marrow transplant
NCT05530239 unknown statusnot on this map

Single-center Pilot Study: Nano-rheological Biomarkers for Patients With Sickle Cell Disease (SCD) Versus Control Subjects (Other Constitutional Red Blood Cell Diseases and Healthy Subjects)

TypeobservationalSponsorUniversity Hospital, GrenobleRan2022 to 2025Enrolled40ConditionsSickle Cell DiseaseArmsBlood sample collection
NCT07023666 phase2recruitingnot on this map

Early Detection and Management of Cardiac Iron Overload in Sickle Cell Disease Using Multimodal Imaging for Improved Clinical Outcomes

TypeinterventionalSponsorInova Health Care ServicesRan2025 to 2027Enrolled100ConditionsSickle Cell DiseaseArmsDeferoxamine, Deferasirox, Deferiprone, Echocardiography, Electrocardiogram (ECG)
NCT07177300 phase4recruitingnot on this map

Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)

TypeinterventionalSponsorChildren's Hospital Medical Center, CincinnatiRan2024 to 2028Enrolled50ConditionsSickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0)ArmsPK-optimized oral hydroxyurea at MTD until 15 years of age.
NCT07708714 phase1 / phase2recruitingnot on this map

Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study

TypeinterventionalSponsorChildren's Hospital Medical Center, CincinnatiRan2026 to 2032Enrolled250ConditionsSickle Cell Disease, Sickle Cell Anemia in ChildrenArmshydroxycarbamide
3 · Its place in the literature

Who cites it

213 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Hydroxyurea (hydroxycarbamide) for sickle cell disease.The Cochrane database of systematic reviews · 2022
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Phytomedicines (medicines derived from plants) for sickle cell disease.The Cochrane database of systematic reviews · 2020
    Pooled it
  7. Guideline
  8. Pooled it
  9. Phytomedicines (medicines derived from plants) for sickle cell disease.The Cochrane database of systematic reviews · 2018
    Pooled it
  10. Hydroxyurea (hydroxycarbamide) for sickle cell disease.The Cochrane database of systematic reviews · 2017
    Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

153 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sophie LanzkronJohns Hopkins School of Medicine, Department of Medicine, Baltimore, MD 21205, USA. slanzkr@jhmi.edu
C Patrick Carroll
Carlton Haywood

Funding

Sickle Cell Disease: First steps toward understanding barriers to care for adultsK23HL083089 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI LANZKRON, SOPHIE M · 2008 to 2012
$701k
Trajectories of Trust Among Patients with Sickle Cell DiseaseK01HL108832 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HAYWOOD, CARLTON · 2011 to 2014
$545k
NHLBI NIH HHS K01 HL108832NHLBI NIH HHS K01HL10883201NHLBI NIH HHS K23 HL083089NHLBI NIH HHS K23HL083089
6 · The paper itself

Abstract

objectivesImprovements in survival for children with sickle cell disease (SCD) during the last 30 years have been well established. Whether similar improvements for adults with the disease have occurred is unknown. We investigated mortality rates for children and adults with SCD.

methodsWe used the National Center for Health Statistics multiple-cause-of-death files to examine age at death and calculate mortality rates from 1979 to 2005. We examined trends in mortality rates using negative binomial regression, and we examined age at death using t-tests and linear regression.

resultsWe identified 16,654 sickle cell-related deaths. Mean age at death was significantly different for males (33.4 years, 95% confidence interval [CI] 33.0, 33.7) than for females (36.9 years, 95% CI 36.5, 37.4). In a regression model controlling for gender, the mean age at death increased by 0.36 years for each year of the study. The median age at death in 2005 was 42 years for females and 38 years for males. The overall mortality rate increased 0.7% (p<0.001) each year during the time period studied. The adult (>19 years of age) mortality rate increased by 1% (p<0.001) each year during the time period studied. The pediatric mortality rate decreased by 3% (p<0.001) each year during the time period studied.

conclusionsThese data confirm prior findings of a significant decrease in mortality for children with SCD. The mortality rate for adults appears to have increased during the same time period. It seems unlikely that this increase is due merely to an influx of younger patients surviving to adulthood and may reflect a lack of access to high-quality care for adults with SCD.

Indexed as

AdolescentAdultAgedAged, 80 and overAge DistributionAnemia, Sickle CellChildChild, PreschoolFemaleHealth Services AccessibilityHumansInfantInfant, NewbornMaleMiddle AgedRegression Analysis

Identifiers

PMID23450875
PMCPMC3560868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.